Skip to main content
Jiaxin Niu, MD, Oncology, Gilbert, AZ, Banner Gateway Medical Center

JiaxinNiuMD

Oncology • Gilbert, AZ

Co-Director of Lung Cancer Program

Join to view full profile

Dr. Niu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Niu's full profile

Already have an account?

Summary

  • I graduated from China Medical University. After that, I pursued Ph.D. in molecular pharmacology at University of Illinois in Chicago, Illinois. I completed internal medicine internship and residency training at Cook County hospital in Chicago, Illinois and subsequently received fellowship training in hematology and oncology at Baylor College of Medicine in Houston, Texas.

    I am triple board-certified in internal medicine, hematology and medical oncology. I joined Banner MD Anderson Cancer Center in 2016 and has been focusing on clinical practice and research in lung, head & neck cancers.

    I have over 20 years of experience in both basic and clinical research. My passion has been early drug development. I am the principal investigator or co-principal investigator of many ongoing clinical trials at BMDACC. Most recently, I participated in Regeneron study as a site-PI, which was published in New England Journal of Medicine in 2018. The study drug, now known as Cemiplimab, was approved by FDA to treat advanced cutaneous squamous cell carcinoma.

    Selected ongoing Clinical trials (25 total)

    1. An Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
    2. A Phase 1 Study of RGX-104 With or Without Nivolumab in Patients with Advanced Solid Malignancies
    3. A Phase 1b Dose-Escalation Study of Cabozantinib Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
    4. A Phase I/II study of HB-201 as monotherapy or in combination with nivolumab in patients with human Papillomavirus 16 positive (HPV 16+) confirmed cancers
    5. A Phase 1 Study Evaluating the Safety and Efficacy of HPV16 E7 T Cell Receptor Engineered T Cells (KITE-439) in HLA-A*02:01+ Subjects with
    Relapsed/Refractory HPV16+ Cancers
    6. A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T

Education & Training

  • Baylor College of Medicine
    Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2007 - 2010
  • Cook County Health and Hospitals System
    Cook County Health and Hospitals SystemResidency, Internal Medicine, 2004 - 2007
  • China Medical University Shenyang
    China Medical University ShenyangClass of 1995

Certifications & Licensure

  • AZ State Medical License
    AZ State Medical License 2011 - 2024
  • IL State Medical License
    IL State Medical License 2004 - 2011
  • TX State Medical License
    TX State Medical License 2009 - 2011

Awards, Honors, & Recognition

  • Top Doctors:Arizona State Castle Connolly, 2013

Clinical Trials

Publications & Presentations

PubMed

Authored Content

  • - Safety and Efficacy of RP1 + Nivolumab in Patients with Non-Melanoma Skin Cancer of the Head and Neck: Results from IGNYTE Phase 1/2 Multi-Cohort Clinical TrialFebruary 2022

Press Mentions

  • Overcoming Immune Blockade in Non-Small Cell Lung Cancer
    Overcoming Immune Blockade in Non-Small Cell Lung CancerApril 19th, 2018
  • Biodesix Blood-Based Diagnostic Testing Approach to PD-L1 Detection Shows Concordance with Immunohistochemistry
    Biodesix Blood-Based Diagnostic Testing Approach to PD-L1 Detection Shows Concordance with ImmunohistochemistryNovember 1st, 2017

Professional Memberships

Hospital Affiliations

Dr. Jiaxin Niu, Dr. Jiaxin Niu, MD, Dr. J Niu